Senate confirms Elbridge Colby for Pentagon policy chief - Breaking The News
Download our appPlay StoreApp Store

Senate confirms Elbridge Colby for Pentagon policy chief

EPA-EFE/YONHAP

The Senate confirmed Tuesday with a 54-45 vote US President Donald Trump's nominee for Under Secretary of Defense for Policy Elbridge Colby.

Trump earlier announced on Truth Social that he had selected Elbridge Colby, who "served with distinction in the Pentagon in my First Term," to fill the role of undersecretary of defense for policy.

Related News
Roche's Q1 sales up 6% to 15.4 billion Swiss francs
F. Hoffmann-La Roche AG said on Thursday its sales in the first quarter of fiscal 2025 reached 15.4 billion Swiss francs, climbing 7% in Swiss francs and 6% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 11.95 billion Swiss francs, while diagnostics division sales amounted to 3.49 Swiss francs, virtually unchanged from the same timeframe in 2024."We had a good start to the year with...
Roche to invest $50B in US pharmaceuticals
F. Hoffmann-La Roche AG announced on Tuesday that it will invest $50 billion in the United States over the next five years.Roche hopes to strengthen already established manufacturing and open new facilities, starting with Indiana, Pennsylvania, Massachusetts, and California. As part of the investment, the number of employees will increase by more than 12,000."Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today's announced...
Pharma stocks drop in Europe amid Trump tariff plans
Stocks of major European pharmaceutical companies, including French Sanofi, British GSK and AstraZeneca, as well as Swiss Roche and Novartis, saw a decline on Wednesday following US President Donald Trump's announcement of a "major tariff" on pharmaceuticals. Trump revealed that Washington would soon impose the tariff, prompting concerns among investors about the potential impact on the global market.At 10:18 am CET, Novartis AG nosedived...
Roche's 2024 sales up 7% to 60.5B Swiss francs
F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.In the year, net income dropped 19% at CER to 9.2 billion Swiss francs...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.